TY - JOUR
T1 - Models of acute myeloid leukemia
T2 - Prospects for drug development and testing
AU - Yin, Bin
AU - Largaespada, David A
PY - 2006/8/24
Y1 - 2006/8/24
N2 - Acute myeloid leukemia (AML) is a common and deadly form of leukemia. New therapies are desperately needed. The availability of appropriate disease model systems is crucial to development of effective treatment. A significant progress in generating and characterizing such model systems has been made in the past decade. Here, the relative benefits of cell lines, transgenic mice and xenografted primary AML model will be compared, along with speculation on new models suitable for AML drug discovery.
AB - Acute myeloid leukemia (AML) is a common and deadly form of leukemia. New therapies are desperately needed. The availability of appropriate disease model systems is crucial to development of effective treatment. A significant progress in generating and characterizing such model systems has been made in the past decade. Here, the relative benefits of cell lines, transgenic mice and xenografted primary AML model will be compared, along with speculation on new models suitable for AML drug discovery.
UR - http://www.scopus.com/inward/record.url?scp=33747440418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747440418&partnerID=8YFLogxK
U2 - 10.1016/j.ddmod.2006.05.002
DO - 10.1016/j.ddmod.2006.05.002
M3 - Review article
AN - SCOPUS:33747440418
SN - 1740-6757
VL - 3
SP - 137
EP - 142
JO - Drug Discovery Today: Disease Models
JF - Drug Discovery Today: Disease Models
IS - 2
ER -